Precision Biosensor

Precision Biosensor Capital Intensity

The Capital Intensity Ratio of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 266.36 %. In the previous year, Capital Intensity Ratio was 271.97 % — a change of -2.06% (lower).

Capital Intensity

266.36 %

YoY

-2.06%

Last updated:

Capital Intensity Ratio of Precision Biosensor is 2025 266.36 % . Capital Intensity Ratio of Precision Biosensor was 2024 271.97 % . It decreases by -2.06% lower compared to the previous year.

The Precision Biosensor Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
271.10 KRW
Jan 1, 2019
342.47 KRW
Jan 1, 2020
486.81 KRW
Jan 1, 2021
350.71 KRW
Jan 1, 2022
288.44 KRW
Jan 1, 2023
306.40 KRW
Jan 1, 2024
271.97 KRW
Jan 1, 2025
266.36 KRW
The Precision Biosensor Capital Intensity history
YEARCapital IntensityYoY
266.36 %-2.06%
271.97 %-11.24%
306.40 %+6.23%
288.44 %-17.76%
350.71 %-27.96%
486.81 %+42.15%
342.47 %+26.32%
271.10 %-22.55%
350.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Capital Intensity Ratio of Precision Biosensor is 266.36 % in 2025.

Capital Intensity Ratio of Precision Biosensor changed from 271.97 % to 266.36 %, representing a -2.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Precision Biosensor

All Key Metrics — Precision Biosensor